Kolon adds TONXBIO as holding-company subsidiary after Kolon Pharm spinoff

• Kolon Corp. folded TONXBIO into its holding-company structure following Kolon Pharm’s spinoff reorganization.
• The holding company took a 40% stake, equal to 532,544 shares, effective Oct. 2, 2026.
• Investment book value totaled 16,422 million, representing 2.16% of Kolon Corp.’s total assets based on year-end 2025 standalone statements.
• TONXBIO’s latest summarized financials showed assets of 39,672 million, liabilities of 770 million, equity of 38,902 million.
• The transaction lifted the group’s total number of subsidiaries to 10 from 9.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kolon Corp. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261012800600), on October 12, 2026, and is solely responsible for the information contained therein.